Related Experiment Video

Updated: Aug 31, 2026

Isolated Pancreatic Islet Treatment and Apoptosis Measurement
09:36

Isolated Pancreatic Islet Treatment and Apoptosis Measurement

Published on: May 2, 2025

Cytokine response to diabetic ketoacidosis and its treatment

William H Hoffman1, C Lynne Burek, Jennifer L Waller

  • 1Department of Pediatrics, Medical College of Georgia, Augusta, GA 30912, USA. whoffman@mail.mcg.edu

Clinical Immunology (Orlando, Fla.)
|September 23, 2003
PubMed

Insights

Diabetic ketoacidosis (DKA) treatment impacts cytokine levels, with initial elevations followed by increases in inflammatory cytokines. These changes correlate with acute complications like brain edema in children.

Area of Science:

  • Pediatric Endocrinology
  • Immunology
  • Metabolic Disorders

Background:

  • Diabetic ketoacidosis (DKA) is a severe complication of diabetes characterized by metabolic crisis.
  • Cellular activation and cytokine release are implicated in DKA's acute complications.
  • Understanding these inflammatory markers is crucial for managing DKA.

Purpose of the Study:

  • To monitor plasma cytokines as indicators of cellular activation in pediatric DKA.
  • To identify potential cytokine markers for DKA acute complication progression.
  • To investigate the effects of DKA treatment on cytokine profiles.

Main Methods:

  • Blood samples collected from six children with severe DKA (pH < 7.2) pre-treatment, during, and post-treatment.
  • Plasma levels of IL-10, IL-1beta, TNF-alpha, IL-6, IL-8, and IL-2 were measured using ELISA.
  • Cytokine levels were analyzed at multiple time points relative to DKA treatment initiation.

Main Results:

  • Elevated plasma cytokines, particularly IL-10, were observed before DKA treatment.
  • DKA treatment led to a significant decrease in IL-10 levels at 6-8 hours.
  • An increase in inflammatory cytokines (IL-1beta, TNF-alpha, IL-8) was noted at 6-24 hours post-treatment compared to baseline.

Conclusions:

  • DKA and its treatment exert differential effects on cellular activation and cytokine release.
  • The observed increase in inflammatory cytokines correlates temporally with the development of edema (brain and pulmonary).
  • Cytokine profiling offers insights into DKA pathophysiology and complication development.

Related Concept Videos

Diabetic Ketoacidosis ll: Pathophysiology01:22

Diabetic Ketoacidosis ll: Pathophysiology

Diabetic ketoacidosis (DKA) is a metabolic emergency characterized by hyperglycemia, ketonemia, and metabolic acidosis. It results from severe insulin deficiency and an excess of counterregulatory hormones, leading to uncontrolled lipolysis, ketogenesis, and widespread electrolyte and fluid disturbances.Pathophysiology The central event in DKA is a profound loss of insulin action. Without insulin, glucose uptake in insulin-dependent tissues is impaired, while hepatic glucose production...
Diabetic Ketoacidosis l: Introduction01:25

Diabetic Ketoacidosis l: Introduction

DefinitionDiabetic ketoacidosis (DKA) is an acute, life-threatening complication of diabetes mellitus, characterized by a triad of hyperglycemia (blood glucose >250 mg/dL), ketonemia or ketonuria, and metabolic acidosis (arterial pH <7.30 and serum bicarbonate <18 mEq/L). It results from insulin deficiency combined with elevated levels of counterregulatory hormones—glucagon, catecholamines, cortisol, and growth hormone—leading to increased lipolysis, hepatic ketone production, and...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...